Arlene Sharpe, MD, PhD

George Fabyan Professor of Comparative Pathology, Head of Division of Immunology and the Interim Co-Chair, Department of Microbiology and Immunobiology, Harvard Medical School
Leader, Cancer Immunology Program at the Dana-Farber/Harvard Cancer Center
Co-Director, Evergrande Center for Immunologic Diseases, HMS and BWH

Arlene is a leader in the field of T cell costimulation. Her laboratory has discovered and elucidated the functions of T cell costimulatory pathways, including the immunoinhibitory functions of the CTLA-4 and PD-1 pathways, which have become exceptionally promising targets for cancer immunotherapy. Her laboratory currently focuses on the roles of T cell costimulatory pathways in regulating T cell tolerance and effective antimicrobial and antitumor immunity, and translating fundamental understanding of T cell costimulation into new therapies for autoimmune diseases and cancer.

Arlene has published over 300 papers and was listed by Thomson Reuters as one of the most Highly Cited Researchers (top 1%) in 2014 and 2015 and a Citation Laureate in 2016. She received the William B. Coley Award for Distinguished Research in Tumor Immunology in 2014 and the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of the PD-1 pathway.

Arlene earned her MD and PhD degrees from Harvard Medical School and completed her residency in Pathology at Brigham and Women’s Hospital.

Ken Smith, FRACP, PhD, FMedSci

Professor of Medicine and Head of Department of Medicine, University of Cambridge

Ken’s laboratory studies basic immunological mechanisms and how defects in regulatory control of the immune system can lead to autoimmunity and alter defence against infection. The lab also runs a translational program in autoimmune disease that has led to the discovery of a prognosis-predicting biomarker entering clinical trials, and to the identification of new pathways driving disease outcomes in autoimmunity and infection.

Along with his laboratory work, Ken is clinically active in nephrology and transplantation at Addenbrooke’s Hospital. He established the Cambridge Immunology Strategic Research Network, directs the FoCIS Cambridge International Centre of Excellence, and led a recent successful bid for funding to establish the Cambridge Institute for Therapeutic Immunology and Infectious Disease, to open in 2018. He is a Wellcome Trust Investigator and an NIHR Senior Clinical Investigator, was elected a Fellow of the Academy of Medical Sciences in 2006, and was awarded the Lister Institute Research Prize in 2007 and the Distinguished Investigator Award of the Lupus Research Institute in 2013.

Ken trained in nephrology and clinical immunology with an interest in autoimmune disease at the University of Melbourne, Australia. His PhD at the Walter and Eliza Hall Institute examined aspects of B cell immunology.

Mark J. Smyth, PhD, FAHMS, FAA

Senior Scientist and Immunology Coordinator, QIMR Berghofer Medical Research Institute Brisbane, Australia

Over the last 20 years, Mark rekindled world-wide interest in cancer immune surveillance, defined immune-mediated dormancy of cancer, and the role of the host in chemotherapy and targeted therapy responses in mice and humans. More recently, he has provided new means of classifying natural killer cell subtypes and identified new targets for cancer immunotherapy.

For his work, Mark received the William B. Coley Award for Distinguished Research in Tumor Immunology in 2002  and the Brupbacher Prize for Cancer Research in 2007 . He is the highest cited immunologist in Australia and is a Senior Editor and Advisory Board Member for Cancer Research and Science, respectively.

Mark completed his PhD in 1988 and trained at the NIH National Cancer Institute, before commencing his independent research career in Australia.

E. John Wherry

Richard and Barbara Schiffrin President's Distinguished Professor of Microbiology
Director, Institute for Immunology, University of Pennsylvania

John has received numerous distinctions for his consistent and significant contributions to infectious disease and cancer research, specifically for his work in helping to identify the role of coinhibitory molecules, including PD-1, and to establish our understanding of T cell exhaustion and immune responses to chronic infections and cancer.

In 2014, John received the distinguished Alumni Award from the Thomas Jefferson University Graduate School of Biomedical Sciences, and in 2016 the Cancer Research Institute’s Frederick W. Alt Award for New Discoveries in Immunology. He has over 175 publications in top international journals including Nature, Science, Nature Immunology, Immunity, and the Journal of Experimental Medicine. His publications have been cited over 34,000 times.

Dr. Wherry received his Ph.D. at Thomas Jefferson University in 2000, then went on to do his postdoctoral research at Emory University, where he trained with Dr. Rafi Ahmed.